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doi:10.1016/j.ejvs.2009.03.023Abstract Objectives: Deep venous thromboses (DVTs) are a significant cause of morbidity
and mortality in the general and inpatient population. Current anticoagulation therapy is effi-
cient in reducing thrombus propagation but does not contribute to clot lysis or prevention of
post-thrombotic limb syndrome. Catheter directed thrombolysis (CDT) is an alternative
method for treating DVTs but there is no consensus regarding indications for its use.
Data sources: PubMed and Cochrane library were searched for all articles on deep vein throm-
bosis and thrombolysis.
Review method: Articles presenting data on DVT thrombolysis, DVT anticoagulation, mechan-
ical thrombectomy, venous stenting and May-Thurner’s syndrome were considered for
inclusion in the review.
Results: CDT reduced clot burden, DVT recurrence and may prevent the formation of post-
thrombotic syndrome. Indications for its use include younger individuals with a long life
expectancy and few co-morbidities, limb-threatening thromboses and proximal ilio-femoral
DVTs. There is a marked lack of randomised controlled trials comparing CDT-related mortality
and long term outcomes compared to anticoagulation alone. The effectiveness of combined
pharmaco-mechanic thrombectomy, although promising, need to be further investigated, as
is the role of caval filters in preventing DVT-associated pulmonary emboli.
Conclusions: These results suggest that the outcome of CDT in DVT management are encour-
aging in selected patient cohorts, but further evidence is required to establish longer term
benefits and cost-effectiveness.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.k, peteholt@btinternet.com (P.J.E. Holt).
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QUORUM Flowchart 
Potentially relevant abstracts identified from PubMed searches (n=179) 
128 excluded as abstracts unsuitable 
Articles retrieved for analysis and evaluation (n=51) 
5 excluded as did not address review 
Articles included in review (n=46) of which 1 randomised controlled trial 
Figure 1 Flowchart demonstrating article selection process.
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Deep venous thromboses (DVTs) affect around 56e122
individuals per 100,000 in the general population per year.1
In the USA, DVTs are responsible for 50,000e200,000 deaths
annually,2 at the same time representing the third com-
monest cardiovascular pathology in the UK after coronary
artery disease and stroke.2
Significant complications associated with DVTs include
pulmonary emboli which cause 10% of inpatient deaths,2
phlegmasia caerulea dolens (PCD) leading to limb-threat-
ening venous gangrene and severe morbidity secondary to
chronic venous hypertension and post-thrombotic syndrome
(PTS).3
PCD is characterised by limb cyanosis and swelling as
a result of thrombosis at a capillary level.2 This is of clinical
importance as it has an associated mortality of 20e41%4,5
and many survivors ultimately develop venous ulceration
and limb loss.
PTS is caused by chronic venous hypertension secondary
to venous reflux, venous obstruction and valvular dysfunc-
tion, with clinical sequelae of leg pain, oedema, venous
trophic changes and chronic ulceration. It is estimated that
up to 80% of patients with a DVT may go on to develop
symptoms of PTS, whilst 4e15% progress to leg ulcer-
ation.6e9
Standard treatment of DVTs involves anticoagulation
with low molecular weight heparin (LMWH) or unfractio-
nated heparin (UH), followed by long term therapy with
vitamin K antagonists, such as warfarin. This has been
shown to effectively reduce the risk of thrombus propaga-
tion or recurrence, pulmonary embolism and death.10
Nevertheless, anticoagulants have little impact on reducing
thrombus size in the short term, being ineffective in the
management of PCD. Furthermore, their inability to cause
thrombus dissolution may not prevent the development of
post-thrombotic limb syndrome in the long term in many
patients.
The feasibility of more invasive techniques aimed at
reducing thrombus burden has gained increasing interest in
recent years. Initially, systemic thrombolysis (with uroki-
nase, streptokinase or tissue plasminogen activator)
demonstrated adequate clot lysis, but exposed patients to
unacceptable side-effects, including intracranial haemor-
rhage, and significant retroperitoneal haematomas. Cath-
eter directed thrombolysis (CDT) involves a focused
delivery of plasminogen activating agents directly into the
thrombus. This may be more effective in local thrombolysis
and restoring venous patency, whilst reducing the risks
associated with systemic therapy.
If CDT presents an effective treatment option for the
management of DVT, then patient selection is of critical
importance in identifying those who would benefit most.
The objective of the article was to review current indi-
cations for DVT thrombolysis.
Data Sources and Review Methodology
A PubMed and Cochrane Library search for ‘deep vein
thrombosis’ and ‘thrombolysis’ was performed. 46 articles
were selected as relevant for the review. These includedarticles addressing the management of May-Thurner’s
syndrome, DVT anticoagulation with heparin and warfarin,
as well as mechanical thrombectomy. Details of article
selection are shown in Fig. 1.
Results
Short term outcome
Lysis and patency rates
Clot lysis may be quantified and stratified according to the
percentage of venous luminal patency restored (Table 1).11
Lysis grades II and III describe greater than 50% of the lumen
as being patent post-lysis and may be considered to be
a satisfactory therapeutic outcome. Current evidence12
demonstrated that CDT achieved superior clot lysis when
compared to a regime of combined heparin and warfarin
therapy (72% vs. 12% patency rate at 6 months),13 with
grade II and III lysis being achievable in both acute ilio-
femoral DVTs (87% of patients) and femoro-popliteal DVTs
(79% of patients).14 This suggested a potential for treating
thromboses at both proximal and distal sites. In addition,
venous patency post CDT has been shown to be maintained
at 6 months post therapy, suggesting longer term advan-
tages over standard anticoagulation (CDT 72% vs.
anticoagulation 12%).3,13 Furthermore, about one third of
CDT-managed DVTs achieved complete clot lysis, which was
associated with a reduction in the risk of recurrent
thrombosis related to residual thrombus.7
Phlegmasia caerulea dolens
Despite a lack of randomised controlled trials, CDT is an
accepted treatment option for PCD. In the light of limited
alternative therapeutic options and a 20e40% associated
mortality,3 CDT assisted by percutaneous or surgical
thrombectomy may be attempted to prevent limb ampu-
tation or death. Nevertheless, the literature comprised
single patient reports or single centre case series, with only
one published randomised controlled trial13 and one large
venous registry series.14 The relative lack of evidence
prevented a definitive conclusion from being drawn
regarding significant treatment benefits in PCD, but in
general the literature was supportive of the role of CDT in
acute limb salvage. Considering the lack of alternative
therapeutic options and little evidence against the use of
CDT for this condition, it would seem pragmatic to support
this treatment pathway.
Table 1 Grade of DVT lysis
Grade I <50% lysis
Grade II 50e99% lysis
Grade III complete lysis
Adapted from Protack et al.11
Table 2 Contraindications for thrombolysis
1. Bleeding diathesis/thrombocytopenia
2. Organ specific bleeding risk (recent MI, CVA, GI bleed,
surgery or trauma)
3. Renal or hepatic failure
4. Malignancy (e.g. brain metastases increase risk of
bleeding)
5. Pregnancy
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The speed of intervention in acute thrombotic events is of
clinical relevance as there is a potential for reversal of
occlusion, relief of symptoms, and preservation of valve
function, which may maximise the potential for reducing
the risk of PTS. It is known that acute thrombi respond
better to thrombolysis compared to established DVTs (86%
vs. 68% significant grade II or III lysis; 34% vs. 19% grade III
lysis)7 due to thrombus organisation over time. Current
evidence suggested that the optimal window for DVT
thrombolysis was within 10 days from onset of symptoms.7
Following this period, thrombus organisation and prolonged
venous hypertension led to worse outcomes and reduce the
likelihood of clot lysis.2,10,15 However, there has been no
formal definition of an acute or chronic DVT from a CDT
perspective and the interventional window of 10 days post-
onset is arbitrary.
Pharmacomechanical therapy
More recent studies have looked at combining CDT and
percutaneous mechanical thrombectomy (PMT). A variety
of devices have been developed to be used alone or in
conjunction with CDT in order to provide a more refined
method of thrombectomy. Their underlying principle
involves isolation of the thrombus between proximal and
distal balloons, local delivery of a thrombolytic agent
followed by mechanical dissolution of the clot using various
physical methods. These include rotating sinusoidal
dispersion wires (Trellis-8, Bacchus Vascular Inc, Santa
Clara, CA), pulsatile saline jets (Angiojet, Possis Medical
Inc, Minneapolis, MN) and low-energy high-frequency
ultrasound (Ekos, Bothell, WA).16 Efferent parts of the
catheter are then used to remove the macerated thrombus
before the proximal balloon is deflated, theoretically reducing
the risk of pulmonary emboli.16,17 Success rates in 80e90%
of patients18e20 have been reported for combined therapy,
with associated reductions in ITU stay and overall hospital
length of stay.21 In particular, ultrasound-accelerated
thrombolysis has been shown to require shorter infusion
time and lower average drug dose compared to catheter
directed thrombolysis alone.22 The role of combined CDT
and PMT requires further investigation to confirm: a. the
effectiveness of PMT and CDT compared to CDT alone in
a randomised trial environment; b. The impact of PMT on
reduced dose of thrombolytic agent used and infusion time;
c. the impact of PMT on incidence of thrombolysis related
pulmonary embolism.15
Complications
Despite the reported effectiveness of CDT in achieving clot
lysis, the endovascular delivery of a thrombolytic agent
may still be associated with significant local and systemic
morbidity and mortality.Bleeding
Most CDT-associated complications were local or systemic
haemorrhagic complications. CDT-related bleeding was
reported to occur in 5e11% of patients,23 higher rates being
associated with prolonged infusion time and high doses of
thrombolytic agent used.14,24 Furthermore, data from the
USA National Venous Registry reported infrequent, but
significant CDT-associated complications, including intra-
cranial haemorrhage (<1%), retroperitoneal haematoma
(1%), musculoskeletal, genitourinary and gastrointestinal
bleeds (3%).7
Despite the possibility of major haemorrhagic compli-
cations, most of the incidents recorded were associated
with puncture site bleeding.25 The routine use of ultra-
sound-guided venous catheterisation can address this issue
by avoiding the risk of multiple punctures, whether arterial
or venous. Further reductions in complication rates may be
achieved by limiting the thrombolytic agent infusion time
and dose,26 in addition to strict enforcement of patient
exclusion criteria (Table 2). Unfortunately these exclude
a large percentage of patients who have developed DVTs
secondary to surgical interventions or trauma, making
thrombolysis a relative therapeutic contraindication.
Pulmonary emboli
There is debate as to whether CDT increases the risk of PE
in the process of clot lysis. PEs occur in up to 30% of general
patients suffering with acute DVTs, many having sub-
clinical presentations.27,28 In CDT-treated DVTs, PEs have
been reported in as many as 4.5% of patients,29 although
most studies suggest a rate closer to 1%.14,25 By comparison,
current data suggests that acute DVTs treated with LMWH
have a symptomatic PE incidence of less than 2%.24
Mortality
Limited data exist regarding CDT-related mortality
compared to anticoagulation alone, although rates of
0e0.4% have been suggested.12,24,30e32 One study however,
suggests a 90-day all-cause mortality of 4%, but insufficient
evidence was available to implicate CDT.33 It is likely that
mortality is a poor outcome measure for this technique,
and that patient reported outcome measures (PROMs),
radiological lysis rates and ultimately the development of
PTS might prove more reliable indicators.
Long term outcome
Recurrent DVTs and the development of PTS are the two
most significant long term consequences of venous throm-
bosis managed with anticoagulation alone.
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PTS is caused by long standing venous obstruction or occlusion,
leading to venous reflux, valvular damage and chronic venous
hypertension. This manifests as ‘bursting’ limb pain, venous
claudication and ulceration, with the attendant morbidity and
loss of function. 90% of DVT patients treated with anticoag-
ulation alone develop some symptoms of venous hypertension
at 5 years.9 Furthermore, 15% develop venous claudication
whilst another 4e15% progress to ulceration.6e9 This reflects
the fact that clot lysis occurs in only 4e12% of patients on
anticoagulants alone,34 making the development of venous
hypertension almost inevitable with this treatment option.
Furthermore, persistent, partially treated venous
thrombi are associated with an increased rate of DVT
recurrence,1 which may be avoided by thrombolysis at the
time of initial presentation. It is evident therefore, that the
long term outcome of anticoagulant therapy is poor with
respect to preventing DVT-associated morbidity, principally
due to its inability to achieve satisfactory clot lysis.
Large ilio-femoral DVTs are most likely to lead to PTS
due to significant proximal residual clot burden and
mechanical stress on venous valves causing destruction and
loss of function. Considering that 70e80% of clinically
significant DVTs25,35 involve the proximal veins, the ability
of CDT to re-establish venous patency in ilio-femoral
thrombosis (87% patency at 6 months, vs. 79% patency in
femoral-popliteal DVTs) provides a strong argument for its
use in the appropriate clinical settings.
Long term venous patency
The ability of CDT to achieve sustainable venous patency is
crucial in determining its role in preventing PTS. It has been
shown that that up to 75%33 of the CDT-treated limbs
demonstrated complete clot lysis at 1 year and that
patency was maintained at 3 years follow-up.11 In addition,
CDT has been shown to reduce long term venous reflux13
compared to anticoagulation alone, reflecting its ability to
preserve valve function and protect against the develop-
ment of PTS. DVT recurrence rates have also been reported
to be low at 6 months (CDT and warfarin vs. anticoagulation
alone: 72% vs. 12% patency rates)10 and 3 years (75% of
patients free of recurrent DVT).11
The inadequate long term outcome of anticoagulation
therapy, combined with the encouraging patency rates of
CDT suggests that thrombolysis may have a role in reducing
PTS and chronic complications of DVTs. However, the lack of
large randomised controlled trials demonstrating this effect
has so far prevented the use of CDT as a first line therapy.
Further answers may be provided by the Norwegian CaVenT
randomised controlled trial (RCT), which has been setup to
investigate the role of CDT vs. conventional therapy in acute
ilio-femoral vein thrombosis.36
Controversies
Comparison of the benefits and limitations of CDT is made
difficult by the heterogeneity of vascular approaches to the
thrombus, thrombolytic agent used, type of infusion cath-
eter employed and concomitant use of endovenous stenting.
Choice of lytic agent
Traditionally streptokinase was used for both local and
systemic thrombolysis, but was associated with an increasedantigenicity and risk of haemorrhage. Consequently, it has
been abandoned in favour of endogenous serine protease
inhibitors such as urokinase and tissue plasminogen
activator.37 In vitro work comparing streptokinase (SK),
urokinase (uPA) and tissue plasminogen activator (tPA)
demonstrated an advantage of uPA in terms of a more rapid
time to clot lysis and an improved fibrinolytic specificity over
SK or tPA.38 The clinical relevance of uPA was supported
by the National Multicentre Venous Registry where 52%
and 31% patients treated with uPA achieved grades II and III
lysis, respectively.14 Associated major bleeding complica-
tions and intracranial haemorrhages occurred in 12.4% and
0.6% of patients in the uPA group compared with 22%
and 2.8% of patients in the tPA group, respectively.39
Nevertheless, others report the rates of intracranial bleeds,
PEs and overall CDT-associated mortality to be close
to 0%.25,40
Venous access
Regarding venous access, Meissner recommended that an
anterograde approach should be used in conjunction with
uPA.12 The National Registry described a variety of access
sites for CDT access, including the popliteal vein (42%), the
common femoral vein (28%), the internal jugular vein (21%)
and the pedal vein (19%). In all cases, ultrasound (US)
guided vascular access was recommended in order to avoid
multiple venous punctures14 and subsequent haematoma
formation.
Venous stents
CDT has the potential advantage of being complemented by
the deployment of augmented by the deployment of
endovascular venous stents should thrombolysis alone fail
or an underlying anatomical abnormalities be identified.
Reported one year patency rates vary between 53e75%
without stenting and 54e89% with stent deployment.14,25,40
More evidence however is needed to establish
whether these achieve any additional patency benefit,
routinely, or whether their use should be limited to
selected cases only.
Caval filters
Caval Filters have been developed to reduce the risk of PEs in
patients with DVTs. However, they have been shown to be
associated with an increased risk of recurrent DVTs (20.8%
vs. 11.6%),41,42 although the association with increase
recurrent DVTrisk was based on unmatched patient groups in
terms of underlying pathology. Furthermore, it is important
to consider the morbidity associated with the additional
interventions of filter insertion and retrieval.
The ability of caval filters to reduce the incidence of PEs
has not been clearly established. Case series have shown
that patients undergoing CDT may have PE-free survival for
up to 3 years in the absence of IVC filters, raising important
questions regarding the role of caval filtration in CDT.11,18
Furthermore, a distinction must be made between PE
caused by thromboembolism during CDT and late embolism
as a result of residual thrombus dislodgement independent
of CDT. Consequently, the rationale for the use of caval
filtration in CDT must depend specifically on the incidence
of CDT-associated PEs, although there is a lack of consensus
regarding this.
Table 3 Possible indications for DVT thrombolysis
1. Extensive thrombosis with high risk of pulmonary
embolisation
2. Ilio-femoral or IVC thrombosis
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context of CDT requires further research before a firm
conclusion can be reached. The role of retrievable filters
must also be addressed, as these may provide short term
protection in the peri-CDT period in those with the highest
risk, whilst potentially avoiding longer term complications
such as increased risk of recurrent DVT.
CDT and thrombosis secondary to anatomical or
structural anomalies
DVTs secondary to an underlying anatomical or structural
cause, such as outflow obstruction through the iliac veins,
have been shown to respond poorly to standard ‘passive’
anticoagulation therapy due to the inability of LMWH to
achieve satisfactory clot lysis.43
Due to the reported high incidence of iliac venous
compression,44 venography and CDT provide a unique
opportunity to distinguish between haemodynamically
significant iliac vein compression and normal anatomical
variants with no clinical consequences. A standard practice
of venography prior to CDT is currently allowing an
increasing number of iliac vein compression syndromes to
be diagnosed and treated, which has reduced the rate of
recurrent thromboses.
A variety of causes for iliac vein compression have been
identified including pelvic tumours, osteophytes, chronic
urinary retention, iliac artery aneurysms, endometriosis,
pregnancy and other uterine masses, such as fibroids.44 The
most commonly documented anatomical variant is May-
Thurner syndrome, in which the left common iliac vein is
compressed by the overlying right common iliac artery.
Venous obstruction is caused not only by direct extra-
luminal compression, but also by intimal changes induced
by vibratory irritation from the overlying pulsatile artery.44
In the absence of endovenous imaging of patients with
DVT, a diagnosis of iliac vein compression is not possible.
However, DVT patients managed with CDT should have
concomitant venography, providing an additional diagnostic
advantage in identifying those anomalies permitting the
definitive treatment of the venous occlusion by balloon
angioplasty and endovascular stent placement following
CDT. In this situation a good outcome may be expected
from combined CDT and stenting, with up to 95% technical
success and patent venous outflow at 2 years’ follow-
up.43,45,46 To highlight this point, in one small series of
May-Thurner patients, whilst 11% of patients treated with
CDT and stents developed stent occlusion, all patients
treated by CDT alone had evidence of re-thrombosis on
follow-up venogram.45,47 Furthermore, the use thrombec-
tomy and anticoagulation alone in the treatment of May-
Thurner’s syndrome may lead to re-thrombosis in almost
three quarters of suffers, highlighting the therapeutic
potential of CDT and stent insertion.45,483. Acute limb compromise
4. Anatomical cause for DVT
5. Good physiological reserve (20e70 years)
6. Life expectancy over 6 months
7. Short onset of symptoms (<14 days)
8. Failure of standard LMWH therapy
9. No contraindications for thrombolysisCost-effectiveness and quality of life
There is a consensus that anticoagulation therapy with
subcutaneous LMWH is a fast, convenient and inexpensive
therapy that can be started in hospital and may be
continued in the community by district nursing or patientself-administration. By contrast, CDT requires repeat
venography which is invasive and increases in-hospital
costs. In addition, CDT may be administered in critical care
setting, with average stay of 12e48 h. Nevertheless, this
must be balanced against the economic burden of PTS and
venous ulceration, with 81% of patients reporting loss of
financial productivity post DVT.49
There is a documented increase in health-related quality
of life in patients receiving CDT at 16 and 22 weeks post
treatment compared to anticoagulation alone.20 Patients
with ilio-femoral DVTs treated by CDT reported superior
overall physical function and fewer symptoms of PTS or
health distress compared to those receiving standard
therapy alone.20
Recommendations for management
Current guidelines from the American College of Chest
Physicians (ACCP) suggest that CDT should be used in
selected patients (good life expectancy >1 year, good
functional status) with extensive venous thrombosis (ilio-
femoral involvement) that have an acute presentation (<14
days).50 The guidelines also advocate the use of venous
angioplasty and stenting in the presence of reversible
causes of thrombosis and highlight the importance of using
CDT and PMT over CDT alone.50
The available data reviewed in our review suggested
that CDTwas effective in achieving superior clot lysis in the
acute setting, with improved long term patency rates over
anticoagulation alone. Clinically, this may translate into
relief of DVT symptoms, an effective management of limb-
threatening thrombosis, and protection against the devel-
opment of PTS. There remains a paucity of data on the long
term outcome of CDT in terms of PTS and this lack of
evidence combined with rare, but significant associated
complications highlight the importance of adhering to strict
patient selection guidelines for CDT. The combination of
CDT with PMT, venous stenting and IVC filtration may
provide superior results in selected groups of patients and
should be further investigated.
The patients most likely to benefit (Table 3) are individ-
uals with a long life expectancy, significant ilio-femoral
thrombosis and those with early presenting DVTs (<14 days).
Patients with a suspected underlying anatomical abnor-
mality may also benefit from the diagnostic and therapeutic
potential of CDT. This population is likely to benefit from
aggressive therapy with subsequent gains in quality of life.
Exclusion criteria for thrombolysis limit the use of CDT in
those patient groups most likely to develop DVTs, such as
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such the target group may include those with out of
hospital DVTs or those with non-operative DVTs (e.g.
sepsis). The outcome of the CaVenT RCT should provide
further guidance regarding exclusion and inclusion criteria
for CDT. More detailed cost-effectiveness analyses
comparing CDT vs. anticoagulation alone are required to
establish a health economic evidence base for this treat-
ment. Finally, encouraging results regarding CDT in the
management of DVTs should not shift clinical focus from
meticulous DVT prophylaxis in all high risk patients.
Conclusions
In selected patients CDT with or without the concomitant
use of venous stenting can improve both short and mid-
term outcomes from proximal DVT. These techniques may
be particularly useful where an anatomical anomaly
underlies thrombus formation, or where there is limb-
threatening ischaemia. Patient selection will be critical to
the success of these techniques. Further randomised
controlled trials are needed to establish the role of
thrombolysis in the management of DVTs.
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